WHITEHAWK THERAPEUTICS INC (WHWK)
NASDAQHealth CareBiotechnologySnapshot 2026-09-09
$4.19-4.56%
Close 2026-09-09 · 1-day change
NASDAQHealth CareBiotechnologySnapshot 2026-09-09
Intact: The reason to own it still holds.
Whitehawk Therapeutics is focused on developing cancer treatment technologies. The company has maintained revenue generation as a priority despite losses. Recent M&A activity could provide new growth opportunities. The stock is cheap compared to peers.
Whitehawk is loss-making with declining revenue, hitting zero in 2026-Q1. Earnings remain negative with no clear path to profitability. The recent selloff reflects elevated risk and weak fundamentals.
The market prices in a re-rating with implied growth of 19.3% over 3 years. Our fair value is $4.93, reflecting cautious optimism. The stock remains risky given ongoing losses and no revenue growth.
Breaks if: Failure to secure capital or complete deals within next 12 months
Breaks if: EPS remains below -1.0 USD per share next 4 quarters
This is not a price target or investment advice.
A long-form read on the 1–3 year hold thesis. It updates when the weekly evidence changes.
This investment represents a speculative growth opportunity in the healthcare sector. The current thesis state is weakened, reflecting concerns about execution quality and overall market conditions.
The market seems to price in a low level of fragility, suggesting that while WHWK is considered cheap compared to peers, there is an expectations gap. This indicates that investors may anticipate some challenges ahead, particularly in execution.
Management is focused on extending the cash runway and advancing clinical programs, with some progress noted. However, the company still faces challenges in managing operating losses, which could impact future performance.
The long-term outlook depends on how management navigates upcoming earnings guidance and the overall health of the job market. Additionally, performance from sector leaders could influence WHWK's trajectory.
The most important moves since the prior daily snapshot.
Yes, our read has weakened. The reason to own WHWK has diminished due to its recent financial performance. It fell from the robust 64th to the 44th percentile of its sector. This change indicates a decline in its standing among peers. However, the latest earnings beat provided some support for the thesis.
as of 2026-09-09
Review the evidence to watch, what would become a concern, and what would make it less concerning.
Not investment advice. Scores describe historical and current data; they are not forecasts of future returns. Consult a licensed advisor before making investment decisions.
Breaks if: revenue remains at or below 0 USD millions next 4 quarters
Sustain efforts to generate revenue despite ongoing operating losses and cash burn.
Over the next 1 to 3 years, WHWK's performance will largely depend on its ability to manage risks and execute on its strategic priorities. Not investment advice.